RAAS 抑制剂不会增加 COVID-19 的风险。
RAAS inhibitors do not increase the risk of COVID-19.
机构信息
Nature Reviews Cardiology, .
出版信息
Nat Rev Cardiol. 2020 Jul;17(7):383. doi: 10.1038/s41569-020-0401-0.
Abstract
According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.
摘要
根据五项新研究，血管紧张素转换酶（ACE）抑制剂或血管紧张素受体阻滞剂（ARB）治疗与感染严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的风险增加或 COVID-19 患者发生严重疾病或住院死亡的风险增加无关。
相似文献
1
RAAS inhibitors do not increase the risk of COVID-19.RAAS 抑制剂不会增加 COVID-19 的风险。
Nat Rev Cardiol. 2020 Jul;17(7):383. doi: 10.1038/s41569-020-0401-0.
2
RAAS Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎风险
N Engl J Med. 2020 Nov 12;383(20):1991-1992. doi: 10.1056/NEJMc2030446. Epub 2020 Oct 27.
3
RAAS Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病风险
N Engl J Med. 2020 Nov 12;383(20):1990-1991. doi: 10.1056/NEJMc2030446. Epub 2020 Oct 27.
4
RAAS Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎风险
N Engl J Med. 2020 Nov 12;383(20):1992-1993. doi: 10.1056/NEJMc2030446. Epub 2020 Oct 27.
5
RAAS Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎风险
N Engl J Med. 2020 Nov 12;383(20):1992. doi: 10.1056/NEJMc2030446. Epub 2020 Oct 27.
6
RAAS Inhibitors and Risk of Covid-19. Reply.肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病风险。回复。
N Engl J Med. 2020 Nov 12;383(20):1993-1994. doi: 10.1056/NEJMc2030446. Epub 2020 Oct 27.
7
RAAS Inhibitors and Risk of Covid-19. Reply.肾素-血管紧张素-醛固酮系统（RAAS）抑制剂与2019冠状病毒病（Covid-19）风险。回复。
N Engl J Med. 2020 Nov 12;383(20):1993. doi: 10.1056/NEJMc2030446. Epub 2020 Oct 27.
8
[Hypertension, RAAS blockade and risk in COVID-19 patients].[高血压、肾素-血管紧张素-醛固酮系统阻断与新冠病毒感染患者的风险]
Lakartidningen. 2020 Jun 23;117:20102.
9
Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019.肾素-血管紧张素系统抑制剂对因2019冠状病毒病住院的高血压患者院内死亡率的临床影响
Clin Infect Dis. 2020 Jul 28;71(15):899-901. doi: 10.1093/cid/ciaa492.
10
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.韩国肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19 感染的相关性。
Hypertension. 2020 Sep;76(3):742-749. doi: 10.1161/HYPERTENSIONAHA.120.15464. Epub 2020 Jul 13.
引用本文的文献
1
Role of the RAAS in mediating the pathophysiology of COVID-19.肾素-血管紧张素-醛固酮系统在介导 COVID-19 病理生理学中的作用。
Pharmacol Rep. 2024 Jun;76(3):475-486. doi: 10.1007/s43440-024-00596-3. Epub 2024 Apr 23.
2
Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review.急性和新冠病毒感染后心血管并发症：全面综述。
Cardiovasc Drugs Ther. 2024 Oct;38(5):1017-1032. doi: 10.1007/s10557-023-07465-w. Epub 2023 May 20.
3
Correlation between structural heart disease and cardiac SARS-CoV-2 manifestations.结构性心脏病与心脏 SARS-CoV-2 表现之间的相关性。
Commun Med (Lond). 2022 Nov 11;2(1):142. doi: 10.1038/s43856-022-00204-6.
4
2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.2022年美国心脏病学会/美国心脏协会临床数据标准特别工作组关于新型冠状病毒肺炎心血管和非心血管并发症的关键数据要素及定义报告
J Am Coll Cardiol. 2022 Jul 26;80(4):388-465. doi: 10.1016/j.jacc.2022.03.355. Epub 2022 Jun 23.
5
2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.2022年美国心脏病学会/美国心脏协会临床数据标准工作组关于新型冠状病毒肺炎心血管和非心血管并发症的关键数据要素及定义报告
Circ Cardiovasc Qual Outcomes. 2022 Jul;15(7):e000111. doi: 10.1161/HCQ.0000000000000111. Epub 2022 Jun 23.
6
It Ain't Over 'Til It's Over: SARS CoV-2 and Post-infectious Gastrointestinal Dysmotility.尚未结束：SARS-CoV-2 与感染后胃肠道动力障碍。
Dig Dis Sci. 2022 Dec;67(12):5407-5415. doi: 10.1007/s10620-022-07480-1. Epub 2022 Mar 30.
7
Hypertension and its management in COVID-19 patients: The assorted view.新型冠状病毒肺炎患者的高血压及其管理：不同观点
Int J Cardiol Cardiovasc Risk Prev. 2021 Dec;11:200121. doi: 10.1016/j.ijcrp.2021.200121. Epub 2021 Nov 13.
8
Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium.探讨 ACEIs/ARBs 使用与 COVID-19 预后的关系：来自比利时全国医院监测数据的多状态建模研究。
BMJ Open. 2021 Sep 16;11(9):e053393. doi: 10.1136/bmjopen-2021-053393.
9
-From One Tissue to Many Cells: A Review of Single-Cell Transcriptomics in Cardiovascular Biology.从一种组织到多个细胞：单细胞转录组学在心血管生物学中的研究进展。
Int J Mol Sci. 2021 Feb 19;22(4):2071. doi: 10.3390/ijms22042071.
10
Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).肾素-血管紧张素-醛固酮系统（RAAS）抑制剂与 2019 年冠状病毒病（COVID-19）。
South Med J. 2021 Jan;114(1):51-56. doi: 10.14423/SMJ.0000000000001200.
本文引用的文献
1
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用与新型冠状病毒病 2019（COVID-19）检测阳性的关联。
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026. doi: 10.1001/jamacardio.2020.1855.
2
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 住院风险的相关性：一项基于病例的队列研究
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
3
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
4
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
5
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
Zotero 插件